Dr. Martens plc
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Onyeije Ogueri Nwokorie
- Full Time Employees
- 2,630
- Sector
- Consumer Cyclical
- Industry
- Apparel - Footwear & Accessories
- Address
- 28 Jamestown Road London United Kingdom NW1 7BY
- IPO Date
- Feb 7, 2022
- Website
- drmartensplc.com
- Similar Companies
- Business
- Dr. Martens plc (LSE: DOCS; OTC: DRMTY) designs, manufactures and sells premium footwear and accessories under the iconic Dr. Martens brand, renowned for its air-cushioned soles, yellow welt stitching and durable construction; core products encompass original silhouettes including the 1460 boot, 1461 shoe, 2976 Chelsea boot and Adrian tassel loafer; emerging families such as Buzz boots and shoes, Zebzag laceless boots and sandals; waterproof variants like the 1460 Rain boot; Kids ranges; sandals; bags including the Weekender and Top Handle; small leather goods; shoe care products; laces and socks. The company operates direct-to-consumer channels comprising 244 owned retail stores and ecommerce alongside wholesale distribution to more than 60 countries across EMEA, Americas and APAC regions; it manufactures at its historic Wollaston, England factory for Made in England lines and in high-volume sites in China, Vietnam, Laos and Thailand; founded in 1960 from a German sole patent originated in 1947, Dr. Martens plc maintains headquarters and global design studio in Camden Town, London. Recent strategic initiatives under a consumer-first growth plan pivot from channel-led to product- and market-focused expansion, delivering full-price direct-to-consumer revenue growth of 6% and shoe volumes up 33% in the first half of fiscal 2026 ended September 28, 2025; new product launches feature the Zebzag Laceless boot, 1460 Rain boot and expanded Buzz and Zebzag lines alongside collaborations with MM6, Palace, MadeMe, Netflix's Wednesday and Rick Owens; distribution partnerships advance into UAE via Beside Group, Latin America (Mexico, Argentina, Paraguay, Chile) through Crosby with stores opened in Buenos Aires and Santiago, Philippines acceleration, Italy franchise and China mono-brand pilots. Operational simplification includes rollout of a Customer Data Platform, Supply and Demand Planning system and Global Technology Centre in India for efficiency gains; store portfolio expanded with 11 net new owned outlets primarily in APAC; gross margin rose 130 basis points to 65.3% amid input cost control despite US tariff headwinds; the firm lists on the London Stock Exchange as a FTSE 250 constituent with around 3,700 employees.
Dr. Martens plc (DRMTY) Q4 2026 Earnings Call Transcript
Dr Martens profits jump as turnaround gains grip
Dr Martens' turnaround gathers pace as annual profit jumps 61%
Dr. Martens plc (DRMTY) Q3 2026 Sales/Trading Call Transcript
Dr. Martens Revenue Drops on Europe, Middle East and Africa Weakness
Dr Martens sales growth slows but 'significant' profit increase still expected
Dr. Martens plc (DRMTY) Q2 2026 Earnings Call Transcript
Dr Martens drops despite results in line with forecasts
Dr Martens back on its feet
Dr Martens tiptoes higher after positive America retail trading, UK still challenging
Dr. Martens: Iconic Brand At A Potential Bargain
Dr Martens surges 23% as investors lace up for recovery story
Dr. Martens plc (DOCMF) Q4 2025 Earnings Conference Call Transcript
Dr Martens marketing 'reset' saw annual revenue and profit retreat, eyes return to growth this year
Dr Martens interims a first test for new CEO after shares stumble to all-time low
Dr. Martens Selects Amperity to Transform Customer Data Strategy
Dr. Martens plc (DOCMF) Q3 2025 Sales/ Trading Statement Call Transcript
Dr Martens flags ‘progress' as constant currency revenue grows
Dr Martens and Ryanair in focus on Monday
Dr Martens recovery plan to be tested in forthcoming update